Yi Zhu
Yi Zhu has a total of 5 co-authors. Here are the top co-authors by number of shared publications:
- Junqiang Lei
Department of Radiology, The First Hospital of Lanzhou University, Lanzhou City, Gansu Province, China
1 shared publication - ShanShan Jiang
Philips Healthcare, Chengdu, China
1 shared publication - Song Tian
Philips Healthcare, Beijing, China
1 shared publication - Yong-Sheng Xu
Department of Radiology, First Hospital of Lan Zhou University, LanZhou, China
1 shared publication - YuanHui Zhu
Department of Radiology, Gansu Provincial Hospital, Lanzhou, China
1 shared publication
Latest Publications
- 10 March 2025
- Published by Springer Nature in Abdominal Radiology
- Vol. 50 (9) , 4087-4099
Automated detection of small hepatocellular carcinoma in cirrhotic livers: applying deep learning to Gd-EOB-DTPA-enhanced MRI
Objectives To develop an automated deep learning (DL) methodology for detecting small hepatocellular carcinoma (sHCC) in cirrhotic livers, leveraging Gd-EOB-DTPA-enhanced MRI. Methods The present retrospective study included a total of 120 patients with cirrhosis, comprising 78 patients with sHCC and 42 patients with non-HCC cirrhosis, who were selected through stratified sampling. The dataset was divided into training and testing sets (8:2 ratio). The nnU-Net exhibits enhanced capabilities in segmenting small objects. The segmentation performance was assessed using the Dice coefficient. The ability to distinguish between sHCC and non-HCC lesions was evaluated through ROC curves, AUC scores and P values. The case-level detection performance for sHCC was evaluated through several metrics: accuracy, sensitivity, and specificity. Results The AUCs for distinguishing sHCC patients from non-HCC patients at the lesion level were 0.967 and 0.864 for the training and test cohorts, respectively, both of which were statistically significant at P < 0.001. At the case level, distinguishing between patients with sHCC and patients with cirrhosis resulted in accuracies of 92.5% (95% CI, 85.1–96.9%) and 81.5% (95% CI, 61.9–93.7%), sensitivities of 95.1% (95% CI, 86.3–99.0%) and 88.2% (95% CI, 63.6–98.5%), and specificities of 87.5% (95% CI, 71.0–96.5%) and 70% (95% CI, 34.8–93.3%) for the training and test sets, respectively. Conclusion The DL methodology demonstrated its efficacy in detecting sHCC within a cohort of patients with cirrhosis. Graphical Abstract
- 10 March 2025
- Published by Springer Nature in Abdominal Radiology
- Vol. 50 (9) , 4087-4099
Automated detection of small hepatocellular carcinoma in cirrhotic livers: applying deep learning to Gd-EOB-DTPA-enhanced MRI
Objectives To develop an automated deep learning (DL) methodology for detecting small hepatocellular carcinoma (sHCC) in cirrhotic livers, leveraging Gd-EOB-DTPA-enhanced MRI. Methods The present retrospective study included a total of 120 patients with cirrhosis, comprising 78 patients with sHCC and 42 patients with non-HCC cirrhosis, who were selected through stratified sampling. The dataset was divided into training and testing sets (8:2 ratio). The nnU-Net exhibits enhanced capabilities in segmenting small objects. The segmentation performance was assessed using the Dice coefficient. The ability to distinguish between sHCC and non-HCC lesions was evaluated through ROC curves, AUC scores and P values. The case-level detection performance for sHCC was evaluated through several metrics: accuracy, sensitivity, and specificity. Results The AUCs for distinguishing sHCC patients from non-HCC patients at the lesion level were 0.967 and 0.864 for the training and test cohorts, respectively, both of which were statistically significant at P < 0.001. At the case level, distinguishing between patients with sHCC and patients with cirrhosis resulted in accuracies of 92.5% (95% CI, 85.1–96.9%) and 81.5% (95% CI, 61.9–93.7%), sensitivities of 95.1% (95% CI, 86.3–99.0%) and 88.2% (95% CI, 63.6–98.5%), and specificities of 87.5% (95% CI, 71.0–96.5%) and 70% (95% CI, 34.8–93.3%) for the training and test sets, respectively. Conclusion The DL methodology demonstrated its efficacy in detecting sHCC within a cohort of patients with cirrhosis. Graphical Abstract